BridgeBio Pharma, Inc.
General ticker "BBIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $13.5B (TTM average)
BridgeBio Pharma, Inc. follows the US Stock Market performance with the rate: 26.5%.
Estimated limits based on current volatility of 1.8%: low 64.26$, high 66.57$
Factors to consider:
- Earnings expected soon, date: 2026-10-28 amc
- Total employees count: 839 (+14.9%) as of 2025
- Top business risk factors: Commercialization failure, Regulatory and compliance, Supply chain disruptions, Labor/talent shortage/retention, Financing access
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [41.82$, 108.59$]
- 2026-12-31 to 2027-12-31 estimated range: [28.25$, 77.63$]
Financial Metrics affecting the BBIO estimates:
- Negative: with PPE of -20.2 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -222.92 <= 7.04
- Negative: Investing cash flow per share per price, % of -0.16 <= -0.14
- Negative: negative Industry operating income (median)
- Negative: 0.33 < Interest expense per share per price, % of 0.35
- Negative: 0.41 < Inventory ratio change, % of 1.27
Short-term BBIO quotes
Long-term BBIO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $9.30MM | $221.90MM | $502.08MM |
| Operating Expenses | $616.67MM | $814.88MM | $1,025.49MM |
| Operating Income | $-607.37MM | $-592.97MM | $-523.41MM |
| Non-Operating Income | $-45.88MM | $50.78MM | $-209.09MM |
| Interest Expense | $81.29MM | $90.99MM | $53.10MM |
| R&D Expense | $455.71MM | $506.46MM | $451.95MM |
| Income(Loss) | $-653.25MM | $-542.19MM | $-732.50MM |
| Taxes | $0.00MM | $1.15MM | $0.43MM |
| Net Income(Loss)* | $-643.20MM | $-535.76MM | $-724.93MM |
| Stockholders Equity | $-1,354.26MM | $-1,467.90MM | $-2,086.61MM |
| Inventory | $0.00MM | $0.00MM | $26.75MM |
| Assets | $546.38MM | $919.34MM | $936.02MM |
| Operating Cash Flow | $-527.72MM | $-520.73MM | $-445.91MM |
| Capital expenditure | $1.31MM | $0.93MM | $1.10MM |
| Investing Cash Flow | $54.03MM | $60.78MM | $-24.49MM |
| Financing Cash Flow | $451.54MM | $748.46MM | $359.29MM |
| Earnings Per Share** | $-3.95 | $-2.88 | $-3.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.